Hutchmed Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Hong Kong, Shanghai& Florham Park, NJ— Monday, May 2, 2022: Hutchmed (China) Limited (“Hutchmed” or the“Company”) (Nasdaq/AIM:HCM; HKEX:13) announced that the U.S. Food and Drug Administration (“FDA”...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news